Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasm Metastasis 8Breast Neoplasms 8Recurrence 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Treatment for Metastatic or Locally Advanced Cervical Cancer 1Thyroid Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Cisplatin 139pembrolizumab 88Carboplatin 73Radiotherapy 71Cetuximab 69Docetaxel 58Paclitaxel 52Radiotherapy, Intensity-Modulated 43Fluorouracil 43Nivolumab 32Surgical Procedures, Operative 18Albumin-Bound Paclitaxel 15130-nm albumin-bound paclitaxel 15Radiation 14Drug Therapy 14tislelizumab 13Taxes 13durvalumab 12Magnetic Resonance Spectroscopy 12toripalimab 11camrelizumab 11Platinum 11Chemoradiotherapy 11Biopsy 11cemiplimab 10Radiosurgery 10Erlotinib Hydrochloride 10Capecitabine 10Specimen Handling 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Squamous Cell Carcinoma of Head and Neck × NVP-BKM120 × Clear all
NCT01852292 2018-07-24

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Novartis

Phase 2 Terminated
157 enrolled 22 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡